Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial

811MO Maintenance olaparib for patients (pts) with newly diagnosed, advanced ovarian cancer (OC) and a BRCA mutation (BRCAm): 5-year (y) follow-up (f/u) from SOLO1

(2020) S. Banerjee et al.   ANNALS OF ONCOLOGY

Current strategies for the targeted treatment of high-grade serous epithelial ovarian cancer and relevance of BRCA mutational status

(2019) Angiolo Gadducci et al.   Journal of Ovarian Research

ESMO–ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease†

(2019) N Colombo et al.   ANNALS OF ONCOLOGY

Final Overall Survival of a Randomized Trial of Bevacizumab for Primary Treatment of Ovarian Cancer

(2019) Krishnansu S. Tewari et al.   JOURNAL OF CLINICAL ONCOLOGY

Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer

(2019) Isabelle Ray-Coquard et al.   NEW ENGLAND JOURNAL OF MEDICINE

Health-related quality of life and patient-centred outcomes with olaparib maintenance after chemotherapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT Ov-21): a placebo-controlled, phase 3 randomised trial

(2018) Michael Friedlander et al.   LANCET ONCOLOGY

Long-term efficacy, tolerability and overall survival in patients with platinum-sensitive, recurrent high-grade serous ovarian cancer treated with maintenance olaparib capsules following response to chemotherapy

(2018) Michael Friedlander et al.   BRITISH JOURNAL OF CANCER

Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer

(2018) Kathleen Moore et al.   NEW ENGLAND JOURNAL OF MEDICINE

Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial

(2017) Eric Pujade-Lauraine et al.   LANCET ONCOLOGY

Bevacizumab and paclitaxel–carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial

(2017) Robert L Coleman et al.   LANCET ONCOLOGY

5th Ovarian Cancer Consensus Conference of the Gynecologic Cancer InterGroup: Recurrent Disease

(2016) M. K. Wilson et al.   ANNALS OF ONCOLOGY

Final overall survival and safety analysis of OCEANS, a phase 3 trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent ovarian cancer

(2015) Carol Aghajanian et al.   GYNECOLOGIC ONCOLOGY

Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial

(2014) Jonathan Ledermann et al.   LANCET ONCOLOGY

The impact of second to sixth line therapy on survival of relapsed ovarian cancer after primary taxane/platinum-based therapy

(2012) L. C. Hanker et al.   ANNALS OF ONCOLOGY

European Network of Gynaecological Oncological Trial Groups' Requirements for Trials Between Academic Groups and Pharmaceutical Companies

(2010) Ignace Vergote et al.   INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER